The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis

Lori P Potter, Susan D Mathias, Monika Raut, Farid Kianifard, Amir Tavakkol, Lori P Potter, Susan D Mathias, Monika Raut, Farid Kianifard, Amir Tavakkol

Abstract

Background: This research was conducted to confirm the validity and reliability and to assess the responsiveness and clinical meaningfulness of the OnyCOE-t, a questionnaire specifically designed to measure patient-reported outcomes (PRO) associated with toenail onychomycosis.

Methods: 504 patients with toenail onychomycosis randomized to receive 12 weeks of terbinafine 250 mg/day with or without target toenail debridement in the IRON-CLAD trial completed the OnyCOE-t at baseline, weeks 6, 12, 24, and 48. The OnyCOE-t is composed of 6 multi-item scales and 1 single-item scale. These include a 7-item Toenail Symptom assessment, which comprises both Symptom Frequency and Symptom Bothersomeness scales; an 8-item Appearance Problems scale; a 7-item Physical Activities Problems scale; a 1-item Overall Problem scale; a 7-item Stigma scale; and a 3-item Treatment Satisfaction scale. In total, 33 toenail onychomycosis-specific items are included in the OnyCOE-t. Clinical data, in particular the percent clearing of mycotic involvement in the target toenail, and OnyCOE-t responses were used to evaluate the questionnaire's reliability, validity, responsiveness, and the minimally clinical important difference (MCID).

Results: The OnyCOE-t was shown to be reliable and valid. Construct validity and known groups validity were acceptable. Internal consistency reliability of multi-item scales was demonstrated by Cronbach's alpha > .84. Responsiveness was good, with the Treatment Satisfaction, Symptom Frequency, Overall Problem, and Appearance Problem scales demonstrating the most responsiveness (Guyatt's statistic of 1.72, 1.31, 1.13, and 1.11, respectively). MCID was evaluated for three different clinical measures, and indicated that approximately an 8.5-point change (on a 0 to 100 scale) was clinically meaningful based on a 25% improvement in target nail clearing.

Conclusion: The OnyCOE-t questionnaire is a unique, toenail-specific PRO questionnaire that can be used with confidence in future studies of toenail onychomycosis. MCID was evaluated for three different clinical measures, and indicated that approximately a 7-point change (on a 0 to 100 scale) was clinically meaningful based on a 12.5% improvement in target nail clearing.

References

    1. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol. 1997;36:754–756. doi: 10.1046/j.1365-4362.1997.00163.x.
    1. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol. 1994;130 Suppl 43:15. doi: 10.1111/j.1365-2133.1994.tb06087.x.
    1. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with onychomycosis. Qual Life Res. 1993;2:341–348. doi: 10.1007/BF00449429.
    1. Lubeck DP, Gause D, Schein JR, Prebil LE, Potter LP. A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res. 1999;8:121–129. doi: 10.1023/A:1026429012353.
    1. Drake LA, Patrick DL, Fleckman P, Andr J, Baran R, Haneke E, Sapede C, Tosti A. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol. 1999;41:189–196. doi: 10.1016/S0190-9622(99)70047-2.
    1. Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998;38:702–704. doi: 10.1016/S0190-9622(98)70199-9.
    1. Pasta DJ, Potter LP. Exploratory Variable Clustering for Integrating Analyses: San Francisco, CA. 1996. pp. 297–301.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Vol. 16. Psychometrika; 1951. pp. 297–334.
    1. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. Cmaj. 1986;134:889–895.
    1. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis. 1987;40:171–178. doi: 10.1016/0021-9681(87)90069-5.
    1. Potter LP, Mathias SD. The OnyCOE-t Questionnaire: Reliability and Validity of a Patient Reported Outcomes Questionnaire: October 19-22; San Francisco, CA. 2005.
    1. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002;11:193–205. doi: 10.1023/A:1015291021312.

Source: PubMed

3
Subskrybuj